BiotechTube
ExploRNA Therapeutics

ExploRNA Therapeutics

Warsaw, Poland· Est.
explorna.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $3M

Overview

ExploRNA Therapeutics is a private, pre-clinical stage biotech firm focused on pioneering innovations within the mRNA therapeutic platform. Its core business model combines a platform technology offering, through the sale of next-generation capping reagents (cap analogs), with internal therapeutic program development in oncology. Led by a team of renowned scientists from the University of Warsaw, including inventor Professor Jacek Jemielity, the company is strategically positioned to capitalize on the growing mRNA therapeutics market by both enabling partners and developing its own novel therapies.

Oncology

Technology Platform

Proprietary next-generation mRNA 5' cap analogs (e.g., AvantCap series) designed to significantly increase mRNA stability and translational efficiency, improving the yield and potency of mRNA therapeutics and vaccines.

Funding History

2
Total raised:$3M
Grant$500K
Seed$2.5M

Opportunities

The validated mRNA market creates strong demand for enabling technologies like superior cap analogs, providing a near-term B2B revenue stream.
The company's internal focus on mRNA-based oncology therapies targets a large and growing market with high unmet need, offering significant upside potential through partnerships or proprietary development.

Risk Factors

The company faces significant competition from established mRNA technology providers and large pharma in oncology.
Its internal therapeutic programs are at an early, high-risk pre-clinical stage with a high likelihood of failure.
As a private, early-stage European biotech, securing sufficient funding for costly clinical development poses a major challenge.

Competitive Landscape

In the mRNA cap analog space, ExploRNA competes with companies like TriLink BioTechnologies (part of Maravai LifeSciences) and Thermo Fisher Scientific. In mRNA therapeutics, it faces competition from giants like Moderna, BioNTech, and CureVac, as well as numerous biotechs. Its differentiation lies in its scientifically deep, founder-led expertise in cap chemistry and its dual platform/therapeutic strategy.

More companies in mRNA Therapeutics →More companies in Poland →